SAN DIEGO — A fentanyl vaccine candidate developed by a team that includes a Scripps Research Institute chemist is moving toward human clinical trials, according to research records and federal funding documents. The vaccine, published in the journal Vaccines in 2022, targets not only fentanyl itself but a range of its dangerous analogs, a feature researchers say sets it apart from other opioid vaccines in development.
The candidate was created by a collaboration between Dr. Colin Haile at the University of Houston and Dr. Kim Janda at the Scripps Research Institute. Janda holds the title of Ely R.
Callaway Jr. Professor of Chemistry and is a member of the Skaggs Institute for Chemical Biology at Scripps Research. His career has focused on hapten-based vaccines—a technology that trains the immune system to recognize small molecules like drugs—and his prior work includes vaccine candidates against cocaine and nicotine. Haile, a research associate professor in the Department of Psychology at the University of Houston, brings expertise in addiction neuroscience and vaccine development.
The record shows their partnership combined Haile’s knowledge of opioid pharmacology with Janda’s background in immunochemistry.
How the vaccine works
The vaccine is designed to stimulate the immune system to produce antibodies that bind to fentanyl molecules in the bloodstream, preventing the drug from crossing the blood-brain barrier. This mechanism would block the euphoric effects of fentanyl, potentially helping individuals in recovery avoid relapse. The broad-spectrum approach against multiple fentanyl analogs is a distinctive feature of this particular candidate, according to the published research.
Janda’s previous work on cocaine and nicotine vaccines provided the scientific foundation for this approach. The opioid crisis, driven heavily by synthetic opioids like fentanyl, has created urgent demand for new treatment tools.
Fentanyl is estimated to be many times more potent than heroin, and illicitly manufactured versions of the drug have flooded the U.S. drug supply in recent years.
Funding and next steps
The National Institutes of Health has provided funding to advance the vaccine toward clinical trials, according to the research team. Clinical trials are the standard regulatory pathway required before any vaccine can be approved for public use. The timeline for those trials has not been publicly specified, but the NIH backing signals federal interest in the approach.
The vaccine candidate is one of several opioid vaccines in development across the country, but its ability to target fentanyl analogs—chemically similar compounds that drug manufacturers sometimes tweak to evade law enforcement—represents a potential advantage. Traditional vaccines often fail against even slightly modified versions of a drug molecule.
On the timeline of the opioid epidemic, the push for a fentanyl vaccine reflects a broader shift in public health strategy. For years, treatment options have centered on medications like methadone and buprenorphine, which work by binding to opioid receptors. A vaccine would offer a different mechanism, one that intercepts the drug before it reaches the brain at all.
Researchers familiar with the field caution that vaccine development for addiction faces unique hurdles. Individuals must be motivated to receive the vaccine and return for booster shots.
The immune response also varies significantly between individuals, and a vaccine cannot reverse an active overdose—it works only as a preventive measure. The collaboration between Haile and Janda represents a fusion of two scientific disciplines: neuroscience and chemistry. Their work, now backed by NIH funding, is among the most advanced efforts to create a broad-spectrum immunological defense against synthetic opioids. Consult your doctor for medical advice.
